Page 2 - Chief Commercialization News Today : Breaking News, Live Updates & Top Stories | Vimarsana

(Reuters) -Bristol-Myers Squibb on Sunday said it will acquire cancer drugmaker Mirati Therapeutics for up to $5.8 billion, diversifying its oncology business and adding drugs it hopes can help offset expected lost revenue from patent expirations later this decade. Bristol will pick up Mirati's portfolio drugs that target the genetic drivers of specific cancers including its lung cancer drug, Krazati, which was approved in December. A second compound - MRTX1719 - which could be used in some types of lung cancer was also attractive to the company, Bristol executives said in an interview.

EconoTimes is a fast growing non-partisan source of news and intelligence on global economy and financial markets, providing timely, relevant, and critical insights for market professionals and those who want to make informed investment decisions.

AFWERX utilizes domestic innovation to address challenging government sector issues. Meet AFWERX’s leaders, founders, and executives here!

Roundup summary of digital health hires and executive board appointments from GHX, QuantHealth, Hopper, Icario, Carenet Health, others

ITHACA, NY, June 14, 2023 (GLOBE NEWSWIRE) -- SimpliFed, the telehealth platform dedicated to virtual breastfeeding and baby feeding support, no matter how you feed your baby, announced today that Mary Hardy will join